mrx-6
Small moleculeexperimental
Clinical trial activity
2 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT00867607)
Timeline
Indications
Mechanism of action
- Phospholipase A2 group 1BINHIBITOR
PLA2G1B inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mrx-6
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02031445 | Phase 2 | Aug 1, 2014 | Celsion, Laniado Medical Center, Maccabi Healthcare Services, Israel, Mayanei Hayeshua Medical Center, Tel Aviv University |
| NCT00867607 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2011 | Hebrew University, Morria Biopharmaceuticals PLC |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celsion | For profit | 1 | 1 | 1 | 2014 |
| Hebrew University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Laniado Medical Center | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Maccabi Healthcare Services, Israel | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Mayanei Hayeshua Medical Center | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Morria Biopharmaceuticals PLC | For profit | 1 | 0 | 1 | 2011 |
| Tel Aviv University | Academic/Hospital | 1 | 0 | 1 | 2014 |
7 organizations
Page 1 / 1